



World Conference on Lung Cancer (WCLC) 2020 in an Hour BTOG Webinar
Wednesday 3rd February 2021
17:30-18:30 BST

Chair: Dr Tom Newsom-Davis – BTOG Steering Committee Vice-Chair

Faculty: Dr Riyaz Shah, Consultant Medical Oncologist, Kent Oncology Centre; Dr Fiona McDonald, Consultant Clinical Oncologist, Royal Marsden Hospital; Professor Richard Booton, Clinical Director for Lung Cancer & Thoracic Surgery and Professor of Respiratory Medicine at Manchester University NHS Foundation Trust and University of Manchester.

BTOG Steering Committee members will present an update on relevant data/research presented at WCLC 2020 (postponed from September 2020 to January 2021) on the topics below.

17:30	Welcome	Tom Newsom-Davis
17:30	Top Medical Oncology Abstracts	Riyaz Shah
17:45	Q&A	Tom Newsom-Davis
17:50	Top Clinical Oncology Abstracts	Fiona McDonald
18:05	Q&A	Tom Newsom-Davis
18:10	Top Respiratory Medicine Abstracts	Richard Booton
18:25	Q&A	Tom Newsom-Davis
18:30	Close	Tom Newsom-Davis

Declarations

1. BTOG confirms that all speakers will introduce themselves and will include as their 1st slide a declaration of conflict of interests and this will be visible to attendees.
2. BTOG confirms there will be a clear view of each speaker's slides. Each speaker will talk to the slides and their voice will accompany the slide discussion (where applicable).
3. BTOG confirms that participants viewing the educational presentations live will be able to submit questions and comments via live webinar chat.
4. BTOG confirms that if RCP approves this live webinar BTOG will provide access via BTOG's online resources and note that CPD will apply to the archived version for four weeks after the event date – we will ensure participants viewing the full archived version will be awarded the appropriate CPD and be issued a certificate of attendance.

Biographies

Professor Richard Booton has been a Consultant Respiratory Physician in the North West Lung Centre for 11 years & Clinical Director for Lung Cancer & Thoracic Surgery at Wythenshawe Hospital since 2018. He is honorary chair in Respiratory Medicine at The University of Manchester. He graduated from The University of Leeds and completed higher specialist training in the North West followed by a fellowship in thoracic oncology at The Christie Hospital and Paterson Institute for Cancer Research with Professor Nick Thatcher receiving a PhD in 2006. Programme Director for the award winning RAPID programme and Manchester Lung Health Check/ Lung cancer screening programme.

His clinical research interests include clinical care in thoracic oncology, advanced bronchoscopy and lung cancer screening. He is a member of the MesoTRAP Trial Steering Group and Principal Investigator (Manchester) for EARL and ELUSIVE multicentre studies, Co-investigator for Yorkshire Lung Screening Trial and Co-chair YLST Biomarker Subgroup. Published over 70 peer-reviewed publications.

Prof Booton has additional affiliations/memberships with the British Thoracic Oncology Group, the Council of Regents, the Communications Committee for the International Association for the Study of Lung Cancer, the Clinical Advisory Group of the National Lung Cancer Audit, the NHSE Expert Advisory Group on Lung Cancer Screening and the NHSE National Delivery Group for Lung Health Checks.

Dr Fiona McDonald has both a private and an NHS practice at The Royal Marsden. She is a Consultant Clinical Oncologist specialising in the treatment of patients with lung cancer.

Dr McDonald studied medical sciences at Cambridge University and was awarded a first-class BA (Hons) degree in 1994. She subsequently qualified from Barts and The London School of Medicine in 1997. After general medical training at St. Mary's Hospital, she completed her specialist oncology training at The Royal Marsden and Guy's and St. Thomas' Hospitals. She was awarded the Frank Doyle Medal from the Royal College of Radiologists in 2002.

She was awarded the president's prize for her research degree at The Institute of Cancer Research between 2008 and 2012 in individualised image-guided adaptive radiotherapy techniques for lung and bladder tumours, including implementation of lung stereotactic radiotherapy for early stage and oligometastatic lung tumours in 2009. She was subsequently appointed as a Consultant Clinical Oncologist at The Royal Marsden in 2012.

Dr McDonald's research aims to improve outcomes by developing individualised approaches to lung radiotherapy through integration of novel functional imaging and targeted biological agents with advanced radiotherapy technologies, including stereotactic/CyberKnife radiotherapy, intensity-modulated and image-guided adaptive radiotherapy. She is the clinical lead for novel developmental work on Magnetic Resonance (MR) guided adaptive radiotherapy for lung tumours.

Dr Tom Newsom-Davis is a consultant in medical oncology at Chelsea and Westminster Hospital, London, where he specialises in thoracic malignancies. He has been a member of the BTOG Steering Committee for the past 2 years, and until recently was part of the National Cancer Research Institute Lung Group and led the RM Partners Cancer Vanguard lung pathway. Dr Newsom-Davis is actively involved in clinical research and has presented his work at a number of national and international meetings. He has been an invited lecturer for various organisations including BTOG, the Royal College of Physicians, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians. In 2015, his work was awarded the Macmillan Innovation Excellence Award.

Dr Riyaz Shah qualified from Guy's and St Thomas Hospitals in 1994 and obtained Membership of the Royal College of Physicians of London in 1997. He completed junior medical training in London and was subsequently awarded an Imperial Cancer Research Fund Clinical Research Fellowship that led to the completion of a PhD from Imperial College/Hammersmith Hospital (1998-2001). His research focused on gene transcriptional irregularities in cancer and gene therapy. Dr Shah completed Medical Oncology training at The Royal Marsden Hospital (2002-2006) before being appointed as a Consultant Medical Oncologist at the Kent Oncology Centre (2006-). He was awarded an ASCO Foundation Merit Award in 2005 for his work in a cancer known as carcinosarcoma.

Dr Shah specialises in thoracic and gastrointestinal malignancies and provides NHS clinics at Darent Valley, Maidstone and Tunbridge Wells Hospitals.

He is active in several local and national committees. At the time of writing he is the Chairman of the Lung Tumour Site Specific Group for the Kent Cancer Collaborative, Lead for Research at KOC, Member of the NCRI Lung Clinical Studies Group and Member of the Thoracic Surgery Clinical Reference Group.

He has a major interest in clinical research and acts as principal investigator on many trials in Kent. He was the UK Chief Investigator of the Lux LUNG 5 trial. He has published widely and is regularly invited to speak at local, national and international meetings.